Skip to main content
Juan Ramón Alaix, CEO of Zoetis, launches Alphaject LiVac in Puerto Montt. Image by Francisco Donoso.
Juan Ramón Alaix, CEO of Zoetis, launches Alphaject LiVac in Puerto Montt. Image by Francisco Donoso.

A new vaccine to help control salmon rickettsial septicaemia (SRS), the most prevalent disease in the Chilean salmonid aquaculture industry, was launched in Puerto Montt last week.  

Called Alpha Ject LiVac SRS, it is the result of many years of hard work and focus by Pharmaq’s R&D team to address an unmet need in the Chilean market.

Zoetis owns Pharmaq and its CEO, Juan Ramón Alaix, began the event by expressing the company’s commitment to aquatic health and acknowledging the excellent work of the Pharmaq team who delivered the first attenuated live SRS vaccine with the support of customers and Chilean regulatory authorities.

Morten Nordstad, Pharmaq President, presented details about the history of the R&D project and the ground-breaking vaccine. His colleagues, Frode Finne-Fridell and Rolf Hetlelid Olsen also shared specifics regarding product safety and efficacy.

“I am very proud that Pharmaq is the first company to deliver an attenuated live SRS vaccine that will help customers develop a sustainable and profitable salmon industry,” said Nordstad. The approval was achieved in record time and is the result of a great team effort, thanks to everyone involved for a fantastic contribution to bring this product to our customers in the Chilean market!”

External speakers provided industry insights and expertise from the Chilean National Fishery and Aquaculture Service (Sernapesca), Salmones Multiexport and Nordea Markets.